1. Home
  2. ONDS vs LQDA Comparison

ONDS vs LQDA Comparison

Compare ONDS & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ondas Holdings Inc.

ONDS

Ondas Holdings Inc.

BUY

Current Price

$8.46

Market Cap

2.8B

ML Signal

BUY

LQDA

Liquidia Corporation

HOLD

Current Price

$32.86

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONDS
LQDA
Founded
2014
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.5B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
ONDS
LQDA
Price
$8.46
$32.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
10
Target Price
$9.60
$37.40
AVG Volume (30 Days)
118.3M
1.8M
Earning Date
11-13-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,748,922.00
$69,216,000.00
Revenue This Year
$406.15
$904.79
Revenue Next Year
$219.04
$188.25
P/E Ratio
N/A
N/A
Revenue Growth
208.40
343.41
52 Week Low
$0.57
$10.37
52 Week High
$11.70
$35.54

Technical Indicators

Market Signals
Indicator
ONDS
LQDA
Relative Strength Index (RSI) 53.96 59.75
Support Level $7.32 $30.50
Resistance Level $9.86 $35.54
Average True Range (ATR) 1.07 1.71
MACD 0.13 0.07
Stochastic Oscillator 62.74 63.62

Price Performance

Historical Comparison
ONDS
LQDA

About ONDS Ondas Holdings Inc.

Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: